Marker Therapeutics (MRKR) Leases (2019 - 2023)
Historic Leases for Marker Therapeutics (MRKR) over the last 5 years, with Q1 2023 value amounting to $5.3 million.
- Marker Therapeutics' Leases fell 4451.8% to $5.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $5.3 million, marking a year-over-year decrease of 4451.8%. This contributed to the annual value of $5.5 million for FY2022, which is 4425.71% down from last year.
- Marker Therapeutics' Leases amounted to $5.3 million in Q1 2023, which was down 4451.8% from $5.5 million recorded in Q4 2022.
- In the past 5 years, Marker Therapeutics' Leases registered a high of $11.1 million during Q3 2020, and its lowest value of $300000.0 during Q2 2020.
- Moreover, its 5-year median value for Leases was $5.6 million (2022), whereas its average is $5.9 million.
- Its Leases has fluctuated over the past 5 years, first plummeted by 4520.1% in 2020, then skyrocketed by 334662.8% in 2021.
- Marker Therapeutics' Leases (Quarter) stood at $455174.0 in 2019, then soared by 2282.41% to $10.8 million in 2020, then fell by 9.35% to $9.8 million in 2021, then crashed by 44.26% to $5.5 million in 2022, then fell by 2.8% to $5.3 million in 2023.
- Its Leases stands at $5.3 million for Q1 2023, versus $5.5 million for Q4 2022 and $5.6 million for Q3 2022.